TABLE 1.
Characteristics of child participants in the study.
| Characteristic | ||
| Median age, years (P25–P75) | 5.75 (2.77–9.61) | |
| Sex, n (%) | ||
| Female | 31 (38.75) | |
| Male | 49 (61.25) | |
| Diagnosis, n (%) | Malignant diseases | |
| Acute myeloid leukemia | 19 (23.75) | |
| Acute lymphoid leukemia | 4 (5.00) | |
| Juvenile granular monocytic leukemia | 2 (2.50) | |
| Myelodysplastic syndrome | 2 (2.50) | |
| Acute biphenotypic leukemia | 2 (2.50) | |
| Chronic granulocytic leukemia | 3 (3.75) | |
| Hemophagocytic syndrome | 4 (5.00) | |
| EBV associated T-cell leukemia | 1 (1.25) | |
| Neuroblastoma | 1 (1.25) | |
| Non-malignant diseases | ||
| Aplastic anemia | 20 (25.00) | |
| Immunodeficiency disease | 8 (10.00) | |
| Thalassemia | 3 (3.75) | |
| Dyskeratosis congenita | 1 (1.25) | |
| Mucopolysaccharidosis | 4 (5.00) | |
| Chronic granulomatous disease | 1 (1.25) | |
| Adrenoleukodystrophy | 1 (1.25) | |
| Congenital thrombocytopenia | 2 (2.50) | |
| Congenital neutropenia | 1 (1.25) | |
| Fucosidosis | 1 (1.25) | |
| Type of transplant, n (%) | ||
| Matched Related | 35 (43.75) | |
| Matched Unrelated | 45 (56.25) | |
| Conditioning regimens, n (%) | ||
| MAC | 57 (71.25) | |
| RIC | 23 (28.75) | |
| BMI at admission, n (%) | ||
| Underweight | 8 (10.00) | |
| Average weight | 69 (86.25) | |
| Overweight or obese | 3 (3.75) | |
| BMI at engraftment, n (%) | ||
| Underweight | 11 (13.75) | |
| Average weight | 66 (82.5) | |
| Overweight or obese | 3 (3.75) | |
| BMI at day + 100 post-HSCT, n (%) | ||
| Underweight | 23 (30.67) | |
| Average weight | 50 (66.67) | |
| Overweight or obese | 2 (2.66) | |
| SCAN at admission, n (%) | ||
| Score ≥ 3 points | 20 (25.00) | |
| Score < 3 points | 60 (75.00) | |
| Weight loss after 100 days post-HSCT, n (%) | ||
| Mean ± SD (kg) | 0.55 ± 2.51 | |
| <5% weight loss | 45 (56.25) | |
| 5–10% weight loss | 15 (18.75) | |
| >10% weight loss | 20 (25.0) | |
| aGVHD, n (%) | ||
| Grade 0-I aGVHD | 47 (58.75) | |
| Grade II-IV aGVHD | 33 (41.25) | |
| acute gastrointestinal GVHD | 31 (38.75) | |
| acute Hepatic GVHD | 17 (21.25) | |
| acute cutaneous GVHD | 2 (2.5) | |
MAC, myeloablative regimens; RIC, reduced intensity conditioning regimens; BMI, body mass index; HSCT, hematopoietic stem cell transplantation; SCAN, nutrition screening tool for childhood cancer; Grade II-IV aGVHD, moderate and severe acute graft versus host disease; and Grade 0-I aGVHD, none and mild acute graft versus host disease.